ClinicalTrials.gov
public full text
Public Domain
Use of Mesenchymal Stem Cells in Inflammatory Bowel Disease
inflammatory-bowel-diseaseinflammatory-bowel-diseasesmesenchymal-stem-cellsneutrophilsulcerative-colitis
Scientists hypothesize that directly or parentally injecting Mesenchymal stem cells (MSCs) to affected areas will have a positive impact through reducing or abolishing intestinal inflammation in part via inhibition of neutrophil Myeloperoxidase (MPOx) activity. Inhibiting MPOx should modify disease progression as well as reduce colitis associated cancer risk.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Early Biomarkers in Circulating α 4β7 + T Cells to Predict Response to Vedolizumab in Inflamatory Bowel Disease Patients.#888940
- The Role of CD4+ T Cell Subsets in the Mechanism of Action of Vedolizumab in Ulcerative Colitis#994728
- ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1#1057376
- Immune-Lymphatic Interactions in Inflammatory Bowel Disease#294896
- An inflammasome-driven differentiation program in intestinal stem cells protects against Salmonella infection.#323163
Record · ID 1113250
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive